Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Business Strategy

Set Alert for Business Strategy

TherapeuticsMD Finds New Exit With Mayne Pharma Licensing Pact

After failure to close of a potential $177m buyout by EW Pharma, TherapeuticsMD will resolve its debt by selling its three-product women’s health portfolio to Mayne.

Deals Business Strategies

Pfizer Backs EU Manufacturing With €2.4bn Investment

Pfizer is betting big on its manufacturing plans in Europe, investing €1.2bn at respective sites in Ireland and Belgium to prepare for a number of launches it has lined up in the short term.

Manufacturing Business Strategies

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: safety debate as more lecanemab data reported; amyloid discussions continue at Alzheimer’s meeting; China COVID unrest affect country’s biotech sector; and Merck’s CMO talks about post-Keytruda plans.

Clinical Trials Business Strategies

Eisai Plots A Meticulous Path To CMS Coverage For Lecanemab

The company believes the Phase III Clarity AD results offer a high level of evidence that may convince the Centers for Medicare and Medicaid Services to change its stance on anti-amyloid antibodies for lecanemab. 

Neurology Market Access

Rigel Ready To Hit The Ground Running After Early AML Drug Approval

Rezlidhia, which was only recently licensed by Rigal from Novo Nordisk-owned Forma Therapeutics, should challenge the market dominance of Servier's Tibsovo in the IDH-1 inhibitor subset of acute myeloid leukemia patients. 

Approvals Business Strategies

Pfizer Returns To Roivant As Development Partner For A Second Time

Roivant will form a new "vant" company to develop and commercialize Pfizer's TL1A inhibitor for ulcerative colitis.

Deals Immune Disorders

Asia Deal Watch: Biocytogen Antibody Candidates To Be Evaluated By ADC Therapeutics

Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.

Deal Watch Business Strategies

Sanofi Makes Big Strides In Eradicating Sleeping Sickness

The positive Phase II/III results for acoziborole have led researchers to claim that the goal of eliminating sleeping sickness by 2030 is now very much a reality.

Infectious Diseases Clinical Trials

Zydus Sees Revlimid Generic Revenues Beyond Q4 As It Waits For Antitrust Suit To Play Out

Zydus, along with Bristol Myers Squibb and generics companies like Mylan, Cipla and Dr. Reddy’s, has been named in an antitrust suit involving BMS’ blockbuster drug Revlimid. For now, it expects revenues from the generic to stretch beyond Q4 FY’23. Meanwhile, a recent acquisition of Watson, which made APIs for the Teva group, should shore up declining API revenues

Commercial Business Strategies

Lessons From Novo Nordisk’s Mads Øvlisen, The Father Of CSR

When Mads Øvlisen was persuaded by his father-in-law to join the family business, Novo Industri, in 1974 for a short stint in the legal department, little did he know it would the beginning of a lifetime of service to the company that he helped to shape into the diabetes powerhouse it is today.

Outlook 2023 Leadership

Nimbus Nips At BMS’s Heels With Psoriasis Results For TYK2 Inhibitor

Without disclosing data, Nimbus announced positive Phase IIb results for NDI-034858 in psoriasis. The company plans to initiate a Phase III trial next year.

Clinical Trials Business Strategies

BioNTech Bolsters Cancer Immunotherapy Ambitions In Pact With Cash-Poor Ryvu

Deal Snapshot: German firm gets license rights to Ryvu’s STING agonist portfolio in addition to collaborating on immunomodulators. Ryvu adds need cash via upfront and equity payments from BioNTech.

Deals Business Strategies
See All
UsernamePublicRestriction

Register